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Summary
Complex communities of microbes live on and in
plants, humans and other animals. These communi-
ties are collectively referred to as the microbiota or
microbiome. Plants and animals evolved to co-exist
with these microbes. In mammals, particular kinds of
alteration of the microbiome (dysbiosis) are associ-
ated with loss of health, most likely due to loss of
microbial metabolites, signalling molecules, or regu-
lators of host pathways. Modern life-style diseases
such as Inﬂammatory Bowel Disease (IBD), Irritable
Bowel Syndrome (IBS), type 2 diabetes, obesity and
metabolic syndrome have been linked to dysbiosis.
These multifactorial diseases involve multiple risk
factors and triggers, depletion of certain gut micro-
biota species being one of them. Live Biotherapeu-
tics operate by restoring microbial products or
activities in affected subjects. They are being devel-
oped as adjuncts, alternatives or new treatment
options for diseases that affect a growing proportion
of global citizens.
Preamble
Complex communities of microbes live on and in plants,
humans and other animals. These communities are col-
lectively referred to as the microbiota or microbiome.
Plants and animals evolved to co-exist with these
microbes. In mammals, particular kinds of alteration of
the microbiome (dysbiosis) are associated with loss of
health, most likely due to loss of microbial metabolites,
signalling molecules or regulators of host pathways.
Modern lifestyle diseases such as inﬂammatory bowel
disease (IBD), irritable bowel syndrome (IBS), type 2 dia-
betes, obesity and metabolic syndrome have been linked
to dysbiosis. These multifactorial diseases involve multi-
ple risk factors and triggers, depletion of certain gut
microbiota species being one of them. Live Biotherapeu-
tics operate by restoring microbial products or activities
in affected subjects. They are being developed as
adjuncts, alternatives or new treatment options for dis-
eases that affect a growing proportion of global citizens.
SDG(s) addressed
Using microbiota for therapeutic purposes contributes
directly to Sustainable Development Goal (SDG) no. 3,
‘Good Health and Well-being’. In fact, live biotherapeu-
tics products (LBPs) can serve either as the main thera-
peutic or as an ‘add-on’ integrating factor; thus, they act
by restoring health or helping and assisting to improve
general well-being. Given that a great deal of intercon-
nections and interdependence exist between SDGs,
improvements of human health are also associated with
reduction in poverty (SDG 1, ‘No Poverty’). In addition,
LBPs promote novel approaches to treatment and in the
medical sciences in general, leading to innovation in the
pharmaceutical industrial sector, which is relevant to
SDG 9 (‘Industry, Innovation and Infrastructure’). Finally,
the concept of the microbiome puts forward a new way
of thinking about the interaction between bacteria and
the human body: these insights are overturning previous
assumptions, thereby endowing knowledge and endors-
ing high-level education (SDG 4, ‘Quality Education’).
Microbiome therapy solution – live biotherapeutics
A LBP is deﬁned by the relevant US regulatory body,
the Food and Drug Administration, as ‘a biological pro-
duct that: (i) contains live organisms, such as bacteria;
(ii) is applicable to the prevention, treatment or cure of a
disease or condition of human beings; and (iii) is not a
vaccine’ (http://www.fda.gov/downloads/BiologicsBlood
Vaccines/GuidanceComplianceRegulatoryInformation/
Guidances/General/UCM292704.pdf). LBPs are concep-
tually similar to probiotics (Hill et al., 2014), but they
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differ in having no association with food, either as an iso-
lation source or as a delivery vehicle; they do not have
the Generally Recognized as Safe (GRAS) or Qualiﬁed
Presumption of Safety (QPS) status that many probiotics
have; their route to market involves a clinical trial/phar-
maceutical regulation pathway like that applied to a new
drug. For a review of LBP deﬁnitions and regulatory con-
siderations, see a recent review (O’Toole et al., 2017).
Live biotherapeutics products, as stated above, are
considered to confer clinical beneﬁt primarily by rectify-
ing the consequences of microbiota alterations. For
example, patients with IBD have a gut microbiome char-
acterized by depletion or over-abundance of speciﬁc
taxa compared to healthy controls(Pascal et al., 2017).
Based on observations that Clostridia group IV and XIVa
species in particular are less abundant in patients with
IBD (Manichanh et al., 2006), one such organism Fae-
calibacterium prausnitzii is being investigated as a candi-
date LBP for IBD, following up on promising ﬁndings in
pre-clinical colitis models (Sokol et al., 2008).
Live biotherapeutics products offer several features
that are consonant with SDG principles and practices
and that confer advantages over other therapeutic
options. LBPs are derived from the microbiome, and
many will be administered with a view to restoring eco-
logical deﬁciencies in the microbiome. They could
potentially provide long-term cures, exempliﬁed by the
high rates of long-term clinical success provided by
faecal microbiota transplantation (Petrof and Khoruts,
2014), a much more extreme ecosystem restoration
than LBP consumption. In some diseases like IBD and
IBS, successful LBP development would eliminate the
need for administering therapeutics like corticosteroids
and selective serotonin receptor antagonists, respec-
tively, that have broad side effects on host physiology.
LBPs may also be useful for restoring a normal micro-
biome interaction network in diseases characterized by
an altered microbiota like IBS (Jeffery et al., 2012), or
in life stages such as ageing (http://www.nu-age.eu/),
or during life events such a stress (http://www.myne
wgut.eu/).
State of the art
The explosion of interest in the microbiome as a deter-
minant of human health has been mirrored by the estab-
lishment of dozens of start-up companies, some allied
with multinational pharmaceutical companies, seeking to
develop LBPs (https://www.cbinsights.com/blog/microb
iome-startups-market-map-company-list/; reviewed in
ref.’s (Olle, 2013; O’Toole et al., 2017)). Some LBPs are
being developed as members of artiﬁcial consortia, e.g.
bacterial spores that aim to prevent Clostridium difﬁcile-
associated diarrhoea (http://www.dilworthip.com/the-eme
rgent-microbiome-a-revolution-for-the-life-sciences-part-i-
rd-leaders/), or a mixture of Clostridia intended to inhibit
inﬂammation (http://www.patentdocs.org/2016/11/guest-
post-the-emergent-microbiome-a-revolution-for-the-life-sc
iences-part-viii-the-microbiome-and-i.html). Administering
consortia is technically challenging but is concordant
with SDG principles because it attempts to restore or
partly restore the original ecosystem balance. Single
LBPs being considered, in development or under evalu-
ation, include Blautia hydrogenotrophica for IBS (http://
www.researchandmarkets.com/reports/3961131/irritable-
bowel-syndrome-pipeline-review-h2#), Eubacterium hallii
for metabolic disease (Udayappan et al., 2016), Lacto-
bacillus reuteri for type 2 diabetes (Mobini et al., 2017)
and Bacteroides fragilis for autism (Abdollahi-Roodsaz
et al., 2016). As stated above, many LBPs under devel-
opment are intended to restore the microbial ecological
network that is typical for a body site in a healthy indi-
vidual. For example, C3J therapeutics is developing
therapeutics that prevent colonization of the oral cavity
by oral pathogens while favouring the colonization by
microbes associated with oral health (https://www.cbin
sights.com/blog/microbiome-startups-market-map-compa
ny-list/). In a different approach, second genome is
using analysis of microbiota alterations and host cellular/
transcriptional responses in patients with IBD to identify
targets and small molecules to treat IBD (Abdollahi-
Roodsaz et al., 2016).
Notwithstanding the excitement and general optimism
of microbiome research, it is important to note in a state-
of-the-art evaluation that microbiome research is still in a
very early stage and that therapeutics derived directly
from microbiome research are not yet in the marketplace
for reasons discussed below.
Obstacles to solutions
The main obstacle to LBP development, which is actu-
ally more of a scientiﬁc and project management chal-
lenge, is to produce good quality phase 1 and phase II
trials to demonstrate safety, tolerance and clinical efﬁ-
cacy. In contrast to testing small molecules through well-
established production practices and trial designs, taking
LBPs through the same process is more difﬁcult
because of the technological features of the organisms
(reviewed in O’Toole et al., 2017). In brief, many of the
organisms of interest are strict anaerobes which requires
extensive modiﬁcation of production processes including
exclusion of oxygen from freeze-drying, formulation and
(if required) encapsulation, all of which must be per-
formed according to good manufacturing practice so that
the product is suitable for human consumption. Placebo
product for controlled trials must be available and must
be indistinguishable to the study participants. The study
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population must be representative of the disease being
targeted, and it may be desirable to at least proﬁle par-
ticipants’ microbiota at baseline, if not stratify patients by
microbiota, to inform evaluation of clinical responses.
Contribution of microbiome therapies
Microbiome therapies and LBPs have opened opportuni-
ties and perspectives that are clearly aligned with the
directions of sustainable development. Their impact on
SDG 3 – ‘Good Health and Well-being’ – is signiﬁcant
as articulated in the previous sections. In addition, these
new tools are providing a different approach for profes-
sionals such as researchers, medical doctors, clinicians
and pharmaceutical experts alike. Interestingly, this
angle has the potential to change the mindset of workers
in the ﬁeld as well as anyone involved in high-level pro-
fessional development and education. The teaching of
microbiome therapies and their underlying concepts
means that the human body will be considered more
carefully not as a single organism but as a host of a
whole community with equilibrium and balance. This is in
line with the philosophy of sustainability rooted through-
out the 169 targets of the SDGs in the United Nations’
2030 Agenda. The contribution of microbiome therapy
research and related advances such as LBPs are likely
to have a ripple effect on a number of topical fora rele-
vant to the SDGs like, for example the ‘One Health Initia-
tive’ (http://www.onehealthinitiative.com/), ecosystem
services and sustainable medicine.
Competing-complementing non-microbial biotech
strategies
Amongst the plethora of non-microbial biotechnology
tools, molecular biotechnology and chemical techniques
dominate the scene. However, microbiome therapy
research ﬁndings have ﬂagged the importance and
advantages of looking beyond molecules and even
beyond cells and organisms: the idea is to strive towards
an all-encompassing view of the microbiome. Micro-
biome therapies and LBPs may provide strategies that
are more amenable to sustainable development in that
they are mindful of the natural state of the body and
work on the maintenance or re-establishing of the equi-
librium of the microbiome. The rational approach used
for microbial strategies and deriving from microbiome
therapies in particular mirrors the vision portrayed in the
SDGs: ‘Technological progress in harmony with nature’
(UN 2030 Agenda; http://anhinternational.org/2015/09/30/
united-nations-sustainable-development-goals-better/).
Concluding remarks
The human microbiome and microbiome therapies in par-
ticular have changed the way in which we think about indi-
vidual plants and animals. Microbiome therapies bring
about a novel approach to treatment and to the way in
which we have conceived the human body. The new phi-
losophy of our body as a collection of populations hosted
by each one of us in a functional equilibrium establishes a
holistic vision with repercussions on health as well as edu-
cation. A strong principle distilled out of the microbiome
research ﬁndings over the last decade is that of balance.
All these concepts are also key pillars of the ideology
of sustainability put forward by the United Nations’ new
2030 Agenda. It is, in fact, not possible to work towards
sustainable development without embracing the need for
equilibrium and balance, which are essential to the envi-
ronment and Earth’s resources, and also extremely rele-
vant, as shown by microbiome research, to the
functioning of the body.
The holistic vision of single human beings being the
cradle of complex communities of microorganisms is in
line with the rationale of sustainability: we ought to con-
sider humans in the same way as the planet, i.e. as
hosts of delicate balance and intricate interdependence.
In turn, we as human individuals depend on the proper
maintenance of the ‘microbiome interactome’ for good
health and general well-being.
As part of the continuing efforts towards education for
sustainable development (ESD) by the UN and
UNESCO, training of scientists and education of the
wider public must include key concepts such as the
ones ﬂagged here if we are to catalyse the change of
mind required for a sustainable future.
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